Exenatide

Drug Profile

Exenatide

Alternative Names: AC 2993; AC002993; AC2993A; Byetta; Exendin 4; LY2148568

Latest Information Update: 24 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amylin Pharmaceuticals
  • Developer AstraZeneca; Eli Lilly; Radboud University; Regional and University Hospital of Besancon
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II/III Metabolic disorders; Type 1 diabetes mellitus
  • Phase II Obesity

Most Recent Events

  • 24 Jul 2017 Exenatide is still in phase III trials for Type-2 diabetes mellitus (In adolescents) in USA, India, Mexico and South Korea (SC) (NCT00658021)
  • 24 Jul 2017 Phase-II/III development for Perioperative stress hyperglycaemia is ongoing in France (IV)(NCT01969149)
  • 24 Jul 2017 No recent reports on development identified - Phase-II for Obesity (Combination therapy) in Sweden (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top